Clinical TrialApr 21, 2026, 04:07 PM
IMRX to Present New Phase 2a Pancreatic Cancer Data at ASCO
AI Summary
Immuneering Corp (IMRX) announced that updated data from its Phase 2a clinical trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients will be presented as an oral presentation at the 2026 ASCO Annual Meeting. The presentation will highlight new survival data from an expanded cohort of 55 first-line patients. CEO Ben Zeskind noted atebimetinib's design to improve survival by shrinking tumors, preserving body mass, and maximizing tolerability.
Key Highlights
- New Phase 2a data for atebimetinib + mGnP in first-line pancreatic cancer.
- Oral presentation at 2026 ASCO Annual Meeting on June 1, 2026.
- Data from an expanded cohort totaling 55 first-line patients.
- Includes initial 34 patients plus an additional 21 patients.
- Atebimetinib designed to promote survival via three distinct mechanisms.
Price Impact
More from IMRX